## Supplementary material

Title: Phenotypic features of CRB1 associated early-onset severe retinal dystrophy and the different molecular approaches to identify the disease-causing variants

Journal name: Graefe's Archive for Clinical and Experimental Ophthalmology

Bohdan Kousal ${ }^{1,2}$, Lubica Dudakova ${ }^{2}$, Renata Gaillyova ${ }^{3}$, Hejtmankova Michaela ${ }^{4}$, Pavel Diblik ${ }^{1}$, Michel Michaelides ${ }^{5,6}$, Petra Liskova ${ }^{1,2 *}$
${ }^{1}$ Department of Ophthalmology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic
${ }^{2}$ Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
${ }^{3}$ Department of Genetics, Faculty Hospital, Brno, Czech Republic
${ }^{4}$ GENNET, Prague, Czech Republic
${ }^{5}$ Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
${ }^{6}$ UCL Institute of Ophthalmology, London, United Kingdom
*Corresponding author:
Petra Liskova, MD, PhD - petra.liskova@lf1.cuni.cz

Supplementary Table 1: Primer sequences of CRB1 gene used in this study (NM_201253.2).

| Exon | Primers 5'- 3' sequence | Tm ( ${ }^{\circ} \mathrm{C}$ ) | Fragment length (bp) |
| :---: | :---: | :---: | :---: |
| 1 | GTGATGCTAAGAAGCACAAAC | 60 | 451 |
|  | CTGACTGTTCACATTGACTGG |  |  |
| 2 | GAGGCAGCACAAAGGTCACA | 60 | 711 |
|  | GAGCTAACTACACCATCTGTG |  |  |
| 3 | ACAGAACATTTGACAAGTGCTC | 60 | 399 |
|  | GCCGAGAACGTGAGAGCTC |  |  |
| 4 | GATGATGCCATGGGTCTTGG | 60 | 318 |
|  | TCATTTGCTATAAGCGATATGTG |  |  |
| 5 | CAGTATAGCAGTCAACCTCC | 60 | 362 |
|  | CAGCTCTTCCTGCTAATACAC |  |  |
| 6 A | TCCATTACAGTCCTAAACCTG | 58 | 575 |
|  | GTAGCCACTTAGCAGCTCC |  |  |
| 6B | CCGAAGCAACAGGGATGTG | 58 | 607 |
|  | TGCTCTGCTCTGAGGCATG |  |  |
| 7 | CTGTCTTTTGAGCCTTAAGATG | 60 | 732 |
|  | CTATACTGGTGGGTCAGTAAC |  |  |
| 8 | CTCTCTGCCACCACTCTGCC | 60 | 526 |
|  | CAGTCAGTATTAGCCTACTCG |  |  |
| 9A | AGCAACTAGCACAGTATGTAAC | 60 | 384 |
|  | CTGACTGCAAACTTGTCAGAC |  |  |
| 9B | CACATTTGGTTTCAGAACAAGG | 60 | 582 |
|  | GACCATCCCAAGGGACAGG |  |  |
| 9 C | CTCTACCAATTCAGTGGTCAC | 60 | 429 |
|  | GACAAGAACAGTGATGCAGAG |  |  |
| 10 | CTTGGCATTGACTACATACATG | 60 | 367 |
|  | GTTTCATTCTGTCTGAACCTC |  |  |
| 11 | GTGCTGTTCCAGAGAGATAAG | 60 | 322 |
|  | CAACTGGCTCGTCATTCATAC |  |  |
| 12 | TCATTCCTGAGTAGTTCCATTG | 60 | 368 |
|  | AGAGATACCTGAAGTACAGTC |  |  |

Supplementary Table 2. In silico analysis of CRB1 missense variants identified in the current study and evaluated as pathogenic. Six different algorithms were used; tolerated and neutral scores are indicated in green as benign; yellow indicates a possibly damaging variant, and red a probably damaging, deleterious, disease-causing mutation. NM_201253.2 and NP_957705 were taken as the reference sequences.

| DNA level | Protein level | SNP\&GO | MutPred | PROVEAN | SIFT | PolyPhen-2 | MutationTaster |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| c.2308G>A | p.(Gly770Ser) | Neutral | Disease | Disease | Neutral | Disease | Disease |
| c.2843G>A* | p.(Cys948Tyr) | Disease | Disease | Disease | Disease | Disease | Disease |
| c.3121A $>G$ | p.(Met1041Val) | Neutral | Possibly <br> damaging | Disease | Neutral | Possibly <br> damaging | Disease |

*Previously reported as disease-causing, summarized in Bujakowska K., et al., 2013.
Using MutPred an overall probability score $>0.5$ was considered as probably disease-causing and a score $>0.75$ was considered as disease-causing.


Supplementary Figure 1. Diagrammatic representation of research approach and workflow applied in the search for the molecular genetic cause in Czech probands with early-onset severe retinal dystrophies.

Time scale indicates the total amount of time spent on the analysis including associated administration to fulfill the national health care system requirements for payment in laboratories located outside the country in probands 1 and 2.

|  | p. 770 |
| :---: | :---: |
| gi\|Homo | S-YGDTISLSMFVRTLQPSGLILALENSTYQYIRVWLERGRLAMLTPNSP |
| gi\|Macaca | S-YGDTVSLSMFVQTLQPSGLLLALENSTYQYIRVWLEHGRLAMLTPNSP |
| gilBos | D-YEEDLTLSMFVRTRRPTGLLLALGNGTYQYLRVWLEHGRLAMLTPGSP |
| gilMus | N-YGQNFSLSMFVRTRQPLGLLLALENSTYQYVSVWLEHGSLALQTPGSP |
| gilRattus | N-FGQNFNLSMFVRTRQPLGFLLTLGNSTYQYVCVWLEHGSLALKTPGSP |
| gi\|Danio | EPDSETLHLSMFLRTRKDSGLLVLLANSTSDYLQMWLEKGKLTVQVNNLK |
|  | : . ****: ${ }^{*}$ : *:*: * *.* :*: $\mathbf{t a * *}^{*}$ * : |


|  | $\text { p. } 948$ |
| :---: | :---: |
| gilHomo | FSPCPHGAQCQPVLQGFECIANAVFNGQSGQILFRSNGNITRELTNITFG |
| gi\|Macaca | FSPCPHEAQCQPVLQGFECIANAVFNEQSSQILFRSNGNITRELTNITFG |
| gi\|Bos | LGPCPPGAQCLRLPRGFECIANAVFNGQSREIIFRSNGNITRELTNITFG |
| gi\|Mus | LSPCPPTAECQLLPQGFECIANAVFSGLSREILFRSNGNITRELTNITFA |
| gi\|Rattus | LSPCPPIAECQLVPQGFECIANAAFSGLSSEILFRSNGNITRELTNITFG |
| gi\|Danio | LNPCPPQAICKALNQGYECISNVTFQEN-TTLVYQGNGLISRHLTSIVFN |
|  | :.*** * * : :*:***:*..*. : : : . ****:*.**.*.* |


|  | $\text { p. } 1041$ |
| :---: | :---: |
| gi\\|Homo | LQSVNDGTWHEVTLSMTDPLSQTSRWQME-VDNETPFVTSTIATGSLNFL |
| gi\|Macaca | LQSVNDGMWHEVTLSMTDPMSQTSRWQME-VDNQTPFVTSTIATGSLNFL |
| gi\|Bos | LQPVSDGVWYQVIISMTDPGAQASRWQME-VDGQTPPVTSAVAAGSLSFL |
| gi\|Mus | SQLVNDGTWHQVTFSMIDPVAQTSRWQME-VNDQTPFVISEVATGSLNFL |
| gi\\|Rattus | SQLVNDGAWHRVTFSMIDPRAQTSLWQME-VDDQTPFVISAVATGNLNFL |
| gi\|Danio | PRVVADGEWHVIELLMATPGSNSSHWIMVPLDEKDEPTKSDSMTGNLDFL |
|  | : * ** *: : : * * : : * * * : : . * :*.*. |

Supplementary Figure 2. Evolutionary conservation of the CRB1 protein. T-Coffee multiple sequence alignment result. Amino acids at position 770, 948 and 1041 in the human CRB1 protein sequence (UniProtKB - P82279) are indicated by an arrow.

